immunotherapy – Page 2 – Oral Cancer News

POISON’s Rikki Rockett wants to get word out about immunotherapy after being declared cancer-free

Source: blabbermouth.net Author: staff Rikki Rockett, drummer for the band POISON, got the best news of his life last week: his cancer is gone. Rockett was diagnosed with oral cancer more than a year ago. Several months ago, he came to Moores Cancer Center at UC San Diego Health, where he underwent experimental cancer immunotherapy, which has now eradicated the tumor. Rockett says he joined the clinical trial not only out of concern about himself, but also about being around for his three-year-old daughter, Lucy, and his seven-year-old son, Jude. Immunotherapy is a relatively new form of treatment that boosts the body's immune system, better enabling it to attack cancer cells. Under the care of Ezra Cohen, MD, professor of medicine and associate director for Translational Science at Moores Cancer Center, Rockett participated in a clinical trial that is testing a combination of two immunotherapy drugs that remove defenses cancers use against the immune system. This type of treatment is only available at a few specific medical centers around the country. "We are delighted that Rikki responded so well to immunotherapy. He had already been through a lot with chemotherapy and radiation treatment before he came to us, but his cancer recurred," said Cohen, who also leads the Solid Tumor Therapeutics Program at Moores Cancer Center, a National Cancer Institute-Designated Comprehensive Cancer Center. "That's the advantage of immunotherapy over traditional therapy — there are fewer side effects, we can specifically eradicate cancer cells almost anywhere in the body, and it's [...]

Oral Cancer Foundation News Team - A2022-09-24T06:56:37-07:00September, 2022|Oral Cancer News|

Pilot study to look at ctDNA results in cancer patients with extraordinary immunotherapy response

Source: web.musc.edu Author: Leslie Cantu Every once in a while, oncologist John Kaczmar, M.D., will have a patient following a course of immunotherapy whose cancer just seems to vanish. “In your heart of hearts, you’re like, ‘Man, I kind of think we might have cured this person,’” said the MUSC Hollings Cancer Center researcher. “Cure” is a word that cancer doctors tend to shy away from, especially in those who have metastatic cancer he said. But Kaczmar is curious about whether those people whose cancer is quickly knocked down – he terms them “extraordinary responders” – could potentially stop immunotherapy treatments sooner. Right now, he said, immunotherapy treatments typically last two years, though there isn’t strong research indicating what the proper length of treatment should be. If doctors and patients were confident that the cancer was gone, they could stop treatment sooner. “Side effects are random in immune therapy. They can happen six months out. They can happen nine months out,” Kaczmar said. “Perhaps some can have a shorter treatment course and avoid immunotherapy toxicity and reduce financial toxicity.” To begin to pull together data, Kaczmar is running a pilot study to look at circulating tumor DNA (ctDNA) in these extraordinary responders. Circulating tumor DNA is DNA from the cancer that can be found in the patient’s blood. Once a specialized lab has a sample of the tumor, collected either from a biopsy or during surgery, the tumor tissue can be sequenced to find the likely cancer mutations and develop [...]

Oral Cancer Foundation News Team - A2022-09-22T05:43:34-07:00September, 2022|Oral Cancer News|

Administering immunotherapy drug before surgery for oral cavity cancer did not increase complications

Source: www.news-medical.net Author: Reviewed by Emily Henderson, B.Sc A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery. The findings were published Aug. 25 in the journal JAMA Otolaryngology - Head & Neck Surgery. Alice Tang, MD, first author on the study, said the research built upon previous findings led by UC's Trisha Wise-Draper that found adding immunotherapy drug pembrolizumab to the standard of care increased survival rates for patients with head and neck cancer with intermediate risk features. Pembrolizumab, sold under the brand name Keytruda, is an antibody used in cancer immunotherapy that treats a variety of cancers, including head and neck. Researchers reviewed outcomes of 32 patients from Wise-Draper's clinical trial who received pembrolizumab before head and neck cancer surgery and 32 control patients to see if the drug led to increased adverse events, including tissue swelling, wound infections, improper wound healing and failure of reconstruction, during and after surgery. "What we found was that patients who received preoperative treatment with immunotherapy did not have an increase in morbidities around the time of surgery," Tang said. Tang said the findings are encouraging as immunotherapy drugs continue to be researched as treatments for head and neck cancer. "For patients who are treatment naïve, meaning that they have not previously received chemotherapy, radiation or surgery for their oral cavity cancer, we can feel reassured that their complication rate would not be different [...]

Oral Cancer Foundation News Team - A2022-09-09T04:30:13-07:00September, 2022|Oral Cancer News|

New discovery could help combat side effects of cancer immunotherapy

Source: news.liverpool.ac.uk Author: staff Researchers in Liverpool and the US have made a breakthrough that could lead to improved immunotherapy treatments for some cancer patients. Their findings, which have been published in Nature, provide critical clues to why many immunotherapies trigger dangerous side effects – and point to a better strategy for treating patients with solid tumours, such as head and neck cancers. The work was led by Professor Christian Ottensmeier, Professor of Immuno-Oncology at the University of Liverpool and a Consultant Medical Oncologist at The Clatterbridge Cancer Centre, and Professor Pandurangan Vijayanand at the La Jolla Institute for Immunology in California. Immunotherapy side effects While immunotherapy has revolutionised the world of cancer treatment, long term disease control is achieved in only around 20 to 30 percent of patients with solid cancers. Immunotherapy can also come at a cost as many patients develop serious problems in their lungs, bowel, and even skin during treatment. These side effects can be debilitating and may force physicians to stop the immunotherapy. When head and neck patients started showing adverse side effects during an immunotherapy trial sponsored and funded by Cancer Research UK’s Centre for Drug Development in a number of cancer centres across the UK, the researchers went back through the data and worked with patient samples to see what went wrong. The patients had been given an oral cancer immunotherapy called a PI3Kδ inhibitor, which are new to the cancer immunotherapy scene, but hold promise for their ability to inhibit “regulatory” T [...]

Oral Cancer Foundation News Team - A2022-05-07T06:27:23-07:00May, 2022|Oral Cancer News|

Gene mutations that contribute to head and neck cancer also provide ‘precision’ treatment targets

Source: www.sciencedaily.com Author: Medical College of Georgia at Augusta University About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable. Keys to targeting that vulnerability include individualized genomic analysis to identify a patient's specific mutation, and finding the drugs that directly target it, investigations that should be given more attention in cancer therapy development, they report in a review article in the journal NPJ Genomic Medicine. The MAPK pathway is a "signaling hub" for cells important to the usual development of the head and neck region, and activating key pathway constituents, like the genes MAPK1 and HRAS, is known to drive the growth of a variety of cancers, says Dr. Vivian Wai Yan Lui, molecular pharmacologist and translational scientist at the Georgia Cancer Center and Medical College of Georgia and the paper's corresponding author. But the mutations in the genes in the MAPK pathway that enable tumor growth can also make it sensitive to drug therapy, says Lui. While a lot of discovery is still needed to find more mutations in the MAPK pathway and the drugs that target them, Lui says they are among the most logical treatment targets for this tough-to-treat cancer. As she speaks, she is looking in her lab for drugs that kill head and neck primary tumors from patients, and at the genetics behind how they [...]

Oral Cancer Foundation News Team - A2022-04-29T05:28:58-07:00April, 2022|Oral Cancer News|

Researchers find new treatment combo effective for head and neck cancer

Source: nocamels.com Author: Simona Shemer Israeli researchers have helped to develop a new treatment combination for patients with advanced or metastatic head and neck cancer (HNC). The treatment, which uses both a targeted drug and immunotherapy following a certain sequence and within a specific time frame, blocks a signaling pathway that suppresses the immune system and keeps it from fighting tumor cells. The research was conducted by an international team of scientists led by PhD student Manu Prasad in the laboratory of Prof. Moshe Elkabets of the Faculty of Health Sciences at the Ben-Gurion University of the Negev. Their findings were just published in the Journal for ImmunoTherapy of Cancer in a study co-authored by Israeli, Chinese, French, German, and US researchers. The researchers targeted an aggressive type of HNC which is driven by the hyperactivation of a specific signaling pathway that will not allow the immune system to kill tumor cells. This was found in more than 40 percent of HNC cases. Head and neck cancers include cancer in the larynx (voice box), throat, lips, mouth, nose, and salivary gland, or malignant tumors that arise from the lining of the head and neck regions. The treatments currently available treatments are ineffective, Prof. Elkabets tells NoCamels. HNC develops in multiple sites on a person and existing treatments, which include chemotherapy, radiation, and immunotherapy have a relatively low response rate of about 20 percent. The average survival rate for patients in Stage III or IV of the disease is only about [...]

Oral Cancer Foundation News Team - A2022-04-09T09:44:07-07:00April, 2022|Oral Cancer News|

Wirral, UK cancer patient trials vaccine

Source: www.wirralglobe.co.uk Author: Craig Manning, Chief Reporter A Wirral man has become the first in the UK to trial a 'vaccine' that is hoped will stop his recurring head and neck cancer from returning. The clinical research team at The Clatterbridge Cancer Centre has given patient Graham Booth an injection of a therapy tailor-made to his personal DNA and designed to help his own immune system ward off cancer permanently. Graham first had head and neck cancer in 2011 and it then returned four times, each time meaning he needed grueling treatment, including facial surgery, reconstruction and radiotherapy. He is now hoping this new treatment – part of the Transgene clinical research study – will mean it does not come back. Dad-of-five Graham, 54, will have a year-long course of immunotherapy injections in a bid to keep him cancer-free, part of a research project designed to reduce deaths and recurrence in head and neck cancers, including of the throat, neck, mouth and tongue. Graham, from West Kirby, said he was not worried about being the first person in the UK to receive this pioneering treatment and that it "opened new doorways" which gave him hope that the cancer would not come back. He added: "When I had my first cancer treatment in 2011, I was under the impression that the cancer would not return. "My biggest fear was realised in 2016 when it came back and then in 2019 and then two cases in 2021. "Last year I had the [...]

Oral Cancer Foundation News Team - A2022-02-07T13:33:09-07:00February, 2022|Oral Cancer News|

Trial underway for novel agent plus immunotherapy for HPV-related head and neck cancer

Source: www.curetoday.com Author: Brielle Benyon Results from a phase 2 clinical trial demonstrated promise for the combination of the novel agent PDS0101 plus Keytruda (pembrolizumab) in treating human papillomavirus (HPV)-associated head and neck cancer. As such, the trial will now progress to full enrollment of 54 patients who have not been previously treated with a checkpoint inhibitor. The trial, VERSATILE-002, involves two groups of HPV16-positive patients with head and neck cancer that is either metastatic or has returned after treatment. One group consists of patients who have no prior treatment with checkpoint inhibition immunotherapy, while the other group is made up of 21 patients whose disease failed checkpoint inhibition — assessment for this group is still ongoing. In the checkpoint inhibitor-naïve group, four or more of the 17 patients achieved an objective response, which was classified by a 30% or more reduction in tumor size. “The achievement of this important milestone in the VERSATILE-002 phase 2 clinical trial strengthens the evidence of our novel Versamune platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, the developer of PFS101, in a statement. “The initial data solidifies our belief that PDS0101’s demonstrated preclinical efficacy when combined with Keytruda has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers.” PDS0101 works by inducing large quantities of CD4+ helper and CD8+ killer T cells, a [...]

Oral Cancer Foundation News Team - A2022-02-03T10:51:38-07:00February, 2022|Oral Cancer News|

Improving head and neck cancer treatment

Source: www.uc.edu Author: Tim Tedeschi, University of Cincinnati News When the medical community finds a treatment for a particular cancer, the work doesn’t stop. Researchers continue to study how treatments can be improved in order to reduce side effects and the possibility of the cancer recurring. University of Cincinnati researchers are leading a new clinical trial to examine if the combination of a more localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer. Chad Zender, MD, said head and neck cancers include cancers of the tongue, throat, tonsil and larynx, and about 30%-50% of patients treated through surgery and radiation will have their cancer return. Patients often then undergo additional surgery and/or radiation treatments, which can lead to side effects like problems with speech and swallowing. “The quality of life is significantly less in the patients that require [subsequent] surgery and then radiation with or without chemo,” said Zender, professor in the Department of Otolaryngology in UC’s College of Medicine, director of head and neck surgery and principal investigator for the new trial. Precision radiation Zender said the trial will test a more localized radiation delivery method through a radioactive seed, about the size of a grain of rice that emits an intense amount of radiation to the cancer and only minimal radiation outside to other areas. The radioactive Cesium-131 seeds are implanted directly into the operative site during surgery. This approach in early studies appears to give more localized radiation [...]

Oral Cancer Foundation News Team - A2022-02-03T10:44:13-07:00February, 2022|Oral Cancer News|

Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck Cancers

Date: November 18th, 2021 Authors: Kaveh Zakeri, MD, MAS, Nancy Y. Lee, MD Source: OncLive The standard of care for patients with locally advanced head and neck squamous cell carcinomas does not substantially differ according to human papillomavirus (HPV) status in the National Comprehensive Cancer Network guidelines.1 Resectable tumors can be treated with surgery followed by adjuvant therapy. Alternatively, definitive chemoradiation therapy with cisplatin is the other dominant treatment paradigm. Incidence of HPV-associated oropharyngeal squamous cell carcinoma has increased rapidly and is associated with higher overall survival (OS) compared with cancers caused by smoking and alcohol.2,3 Given the unique biology of HPV-associated oropharyngeal disease, a separate staging system was developed for these tumors.4 HPV-associated oropharyngeal cancers are more radiosensitive and chemosensitive than cancers caused by smoking and alcohol, yet the traditional treatment paradigms—including high doses of radiation and chemotherapy—were developed prior to the epidemic of HPV-associated disease. De-escalation of therapy has been proposed for HPV-associated oropharyngeal cancer based on data demonstrating high OS and progression-free survival (PFS).5 De-escalation of therapy has been investigated for both definitive surgical and chemoradiation therapy paradigms. Most de-escalated approaches focus on selecting patients according to clinical features, such as disease stage and smoking status, whereas personalized de-escalation reduces treatment intensity for patients according to treatment response. Transoral Robotic Surgery Followed by Adjuvant Radiotherapy Transoral robotic surgery (TORS) is a minimally invasive approach that reduces morbidity compared with traditional, open surgery for patients with oropharyngeal cancers. TORS is a standard of care option for patients with [...]

Charlotte Parker2021-12-06T11:00:39-07:00December, 2021|Oral Cancer News|